Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Journal of Korean Medical Science ; : 40-45, 2006.
Artículo en Inglés | WPRIM | ID: wpr-181120

RESUMEN

TNF-alpha mediated apoptosis of the hematopoietic cells has been thought to contribute to the ineffective hematopoiesis observed in myelodysplastic syndrome (MDS). The combination of pentoxifylline (P) and ciprofloxacin (C) has been shown to reduce the serum levels of TNF-alpha, and an earlier trial of P and C with dexamethasone (D) provided good palliation for patients with MDS. The purpose of this study is to assess the hematologic response to PCD therapy for patients suffering with MDS. 21 of 25 patients who completed at least of 12 weeks of treatment were evaluable for the treatment efficacy. At baseline, the patient's median age was 60 yr (range: 18-75 yr). The diagnoses according to WHO classification included: RA (n=5), RCMD (n=10), RARS (n=1), RCMD/RS (n=1), RAEB (3), and CMML (n=1). 11 patients (52%) had at least single lineage response. 3 patients (11%) showed improvement of triple lineage cytopenia. There were no differences in the response rates between the FAB subtypes. The median time to response was 4 weeks (range: 2-12 weeks), and it is interesting that 9 of 11 patients who had a response remained without relapse for a median of 177 days (range: 78-634 days). These preliminary results indicate that anti-cytokine therapy with PCD is an effective and well tolerated palliative treatment for patients with MDS.


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antiinfecciosos/efectos adversos , Antiinflamatorios/efectos adversos , Apoptosis/efectos de los fármacos , Ciprofloxacina/efectos adversos , Estudio Comparativo , Dexametasona/efectos adversos , Quimioterapia Combinada , Recuento de Eritrocitos , Fármacos Hematológicos/efectos adversos , Síndromes Mielodisplásicos/sangre , Náusea/inducido químicamente , Pentoxifilina/efectos adversos , Recuento de Plaquetas , Factores de Tiempo , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/metabolismo
2.
J. bras. med ; 86(1/2): 21-34, jan.-fev. 2004. ilus
Artículo en Portugués | LILACS | ID: lil-412096

RESUMEN

Trabalho de atualização relativo ao atendimento inicial de pacientes vitimados por hemorragias digestivas agudas, com ênfase à imediata reposição volêmica, de qualidade judiciosamente selecionada. A análise das propriedades farmacológicas da medicação anti-hemorrágica e os bons resultados obtidos dirimem dúvidas e controvérsias relativas ao emprego das mesmas. A listagem de medicamentos e procedimentos que devem ser suprimidos no atendimento de pacientes que sangram e mesmo naqueles cuja hemorragia tenha cessado constitui importante alerta para os que, inadivertidamente, praticam essas iatrogenias. As bases fisiopatológicas apresentadas endossam a advertência. O tratamento endoscópico direto e o uso do balão de Sengstaken-Blakemore serão abordados em futura publicação


Asunto(s)
Humanos , Hemorragia Gastrointestinal , Transfusión Sanguínea , Transfusión Sanguínea , Fármacos Hematológicos/efectos adversos , Analgésicos , Anticoagulantes , Hipovolemia , Somatostatina , Tipificación y Pruebas Cruzadas Sanguíneas , Vasopresinas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA